FOR IMMEDIATE RELEASE
- Expansion introduces additional physician-directed longevity, wellness, and complementary technology capabilities
- Investment builds on Cellgenic’s parallel laboratory expansion in the same city
- Cellular Hope Institute positions Cancun as a comprehensive destination for international regenerative medicine and longevity patients
MIAMI, FL — Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced a significant expansion of its clinical facilities in Cancun, Mexico, introducing additional physician-directed longevity, wellness, and complementary technology capabilities.
The expansion adds hyperbaric medicine, red-light/photobiomodulation therapies, PEMF, radiofrequency technologies, molecular hydrogen therapies, EBOO/EVO, and therapeutic plasma exchange (TPE) to the institute’s clinical capabilities.
The expansion is designed to create a more comprehensive destination for international patients seeking physician-directed regenerative medicine and longevity programs, and complements Cellgenic’s parallel laboratory expansion in the same city. Cellular Hope Institute was clear that all programs remain physician-directed and made no claims regarding specific health outcomes.
“Patients traveling internationally for longevity and regenerative medicine care want more than a single treatment — they want a comprehensive, physician-directed program,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This expansion is about building that in Cancun.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellular Hope Institute
Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), is based in Cancun, Mexico, and provides physician-directed regenerative medicine, longevity, and wellness programs to international patients.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
